Source:http://linkedlifedata.com/resource/pubmed/id/21221482
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
5
|
pubmed:dateCreated |
2011-1-11
|
pubmed:abstractText |
It has been demonstrated that HLA-B*5701 screening reduces the risk for hypersensitivity reaction to abacavir in HIV-infected patients. Since B*5701 prevalence varies among different populations, it is important to determine the carrier frequency prior to its use for the screening of HIV-infected patients.The aim of this study was to determine HLA-B*5701 carrier frequency in Chilean general population and HIV-infected patients referred for B*5701 typing. For that purpose 300 blood bank donors and 492 abacavir-naïve HIV-infected patients from Chile were screened for B*5701 by a sequence specific primer PCR.We detected 14/300 (4.7%) B*57-positive individuals in the Chilean general population, 11 (3.7%) were B*5701 positive, and 3 (1%) had another subtype.All were heterozygous,thus a B*5701 allele frequency of 2% was determined.Eleven of 492 (2.2 %) HIV-patients carried a B*5701 allele. The difference between these frequencies is probably due to slow progression of HIV infection in HLA-B*5701 carriers, thus less patients would require antiretroviral therapy and B*5701 typing. Considering the usefulness of B*5701 screening, its prevalence in the Chilean general population,and the availability of a validated method,we conclude that HLA-B*5701 typing in Chilean HIV-infected patients about to initiate abacavir treatment is strongly recommended.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Anti-HIV Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Dideoxynucleosides,
http://linkedlifedata.com/resource/pubmed/chemical/HLA-B*57:01 antigen,
http://linkedlifedata.com/resource/pubmed/chemical/HLA-B Antigens,
http://linkedlifedata.com/resource/pubmed/chemical/abacavir
|
pubmed:status |
MEDLINE
|
pubmed:issn |
1678-4391
|
pubmed:author | |
pubmed:issnType |
Electronic
|
pubmed:volume |
14
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
510-2
|
pubmed:dateRevised |
2011-11-17
|
pubmed:meshHeading |
pubmed-meshheading:21221482-Anti-HIV Agents,
pubmed-meshheading:21221482-Chile,
pubmed-meshheading:21221482-Dideoxynucleosides,
pubmed-meshheading:21221482-Drug Hypersensitivity,
pubmed-meshheading:21221482-Gene Frequency,
pubmed-meshheading:21221482-Genotype,
pubmed-meshheading:21221482-HIV Infections,
pubmed-meshheading:21221482-HLA-B Antigens,
pubmed-meshheading:21221482-Humans,
pubmed-meshheading:21221482-Polymerase Chain Reaction,
pubmed-meshheading:21221482-Prevalence,
pubmed-meshheading:21221482-Prospective Studies
|
pubmed:articleTitle |
HLA-B*5701 frequency in Chilean HIV-infected patients and in general population.
|
pubmed:affiliation |
Department of Clinical Laboratories, Pontificia Universidad Católica de Chile, Santiago, Chile. hpoggi@med.puc.cl
|
pubmed:publicationType |
Journal Article
|